{"id":113908,"date":"2025-07-31T12:27:00","date_gmt":"2025-07-31T15:27:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/"},"modified":"2025-07-31T12:27:00","modified_gmt":"2025-07-31T15:27:00","slug":"emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/","title":{"rendered":"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO"},"content":{"rendered":"\n<div class=\"xn-content\">\n<p><span class=\"legendSpanClass\">SINGAPURA<\/span>, <span class=\"legendSpanClass\">31 de julho de 2025<\/span> \/PRNewswire\/ &#8212; A Emerald Clinical Trials, uma das principais organiza\u00e7\u00f5es globais em pesquisa cl\u00ednica, anunciou hoje uma transi\u00e7\u00e3o de lideran\u00e7a. Mary\u00a0Gunn deixou o cargo imediatamente.\u00a0A diretoria nomeou Glenn Kerkhof, membro antigo da diretoria e experiente executivo de CRO, como CEO interino.<\/p>\n<div id=\"prni_dvprnejpg4da2left\" dir=\"ltr\" style=\"width: 800px;text-align: left\"><img decoding=\"async\" id=\"prnejpg4da2left\" style=\"width: 400px;height: 181px\" title=\"Emerald Clinical Trials\" src=\"https:\/\/mma.prnewswire.com\/media\/2657673\/5437419\/George_Clinical__Emerald_Clinical_Trials__logo.jpg\" alt=\"Emerald Clinical Trials\" align=\"middle\" \/> <\/div>\n<p>A diretoria iniciou uma busca formal por um CEO permanente e pediu a Glenn Kerkhof que liderasse a organiza\u00e7\u00e3o durante esse per\u00edodo para garantir a continuidade, a estabilidade e uma execu\u00e7\u00e3o s\u00f3lida.<\/p>\n<p>&#8220;Agradecemos a Mary por suas contribui\u00e7\u00f5es&#8221;, disse Sean Carney, presidente da diretoria. &#8220;A Emerald Clinical Trials \u00e9 uma CRO l\u00edder com recursos globais e, com Glenn como CEO interino, estamos confiantes em nossa capacidade de manter o \u00edmpeto e entregar resultados aos nossos clientes&#8221;, disse Sean Carney.<\/p>\n<p>Glenn Kerkhof traz mais de 30 anos de experi\u00eancia executiva em pesquisa cl\u00ednica e servi\u00e7os farmac\u00eauticos.\u00a0Glenn foi anteriormente CEO da Chiltern, onde liderou a empresa atrav\u00e9s de uma grande expans\u00e3o internacional, e atuou como presidente executivo da George Clinical (agora Emerald Clinical Trials), ajudando em seu crescimento em toda a \u00c1sia.<\/p>\n<p>&#8220;Os pontos fortes da Emerald Clinical est\u00e3o em nosso foco terap\u00eautico, profundidade cient\u00edfica e parcerias estreitas com clientes&#8221;, disse Glenn Kerkhof. &#8220;Estou focado em uma transi\u00e7\u00e3o suave, entrega forte para os clientes e apoio \u00e0s nossas equipes globais. Estou comprometido em aproveitar nosso \u00edmpeto e liderar com clareza e prop\u00f3sito&#8221;, disse ele.<\/p>\n<p><b>Sobre a Emerald Clinical Trials<br \/><\/b>A Emerald Clinical Trials \u00e9 uma organiza\u00e7\u00e3o l\u00edder em pesquisa cl\u00ednica que opera em todo o mundo e atende mais de 100 empresas de biotecnologia e 6 das 10 principais empresas farmac\u00eauticas. Com sede em Singapura e norteada por expertise operacional e excel\u00eancia cient\u00edfica, a empresa fornece servi\u00e7os abrangentes de ensaios cl\u00ednicos para clientes em todo o mundo, oferecendo solu\u00e7\u00f5es em todas as fases do ensaio. Para mais informa\u00e7\u00f5es, acesse\u00a0<span><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=4478056-1&amp;h=702930045&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4478056-1%26h%3D1589821538%26u%3Dhttps%253A%252F%252Fwww.emeraldclinical.com%26a%3Dwww.emeraldclinical.com&amp;a=www.emeraldclinical.com\" target=\"_blank\" rel=\"nofollow\">www.emeraldclinical.com<\/a><\/span>.<\/p>\n<p>Logotipo &#8211;\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=pt&amp;o=4478056-1&amp;h=2295929676&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4478056-1%26h%3D1781389118%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F2657673%252F5437419%252FGeorge_Clinical__Emerald_Clinical_Trials__logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F2657673%252F5437419%252FGeorge_Clinical__Emerald_Clinical_Trials__logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2657673%2F5437419%2FGeorge_Clinical__Emerald_Clinical_Trials__logo.jpg\" target=\"_blank\" rel=\"nofollow\">https:\/\/mma.prnewswire.com\/media\/2657673\/5437419\/George_Clinical__Emerald_Clinical_Trials__logo.jpg<\/a><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n<img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PT40510&amp;sd=2025-07-30\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo-302518825.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/br\/comunicados-para-a-imprensa\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo-302518825.html<\/a><\/p>\n<p>FONTE Emerald Clinical Trials<\/p>\n<\/p><\/div>\n<p>  <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT40510&amp;Transmission_Id=202507300800PR_NEWS_LATAM____PT40510&amp;DateId=20250731\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n<p><strong>T\u00f3picos Relacionados:<\/strong> M\u00e9dico \/ Farmac\u00eautico, Produtos Farmac\u00eauticos, An\u00fancios de Pessoal, Sa\u00fade\/Hospitais, Computador\/Eletr\u00f4nica<\/p>\n<p>A <b>OESP<\/b> n\u00e3o \u00e9(s\u00e3o) respons\u00e1vel(is) por erros, incorre\u00e7\u00f5es, atrasos ou quaisquer decis\u00f5es tomadas por seus clientes com base nos Conte\u00fados ora disponibilizados, bem como tais Conte\u00fados n\u00e3o representam a opini\u00e3o da <b>OESP<\/b> e s\u00e3o de inteira responsabilidade da <b>PR Newswire Ltda<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"SINGAPURA, 31 de julho de 2025 \/PRNewswire\/ &#8212; A Emerald Clinical Trials, uma das principais organiza\u00e7\u00f5es globais em pesquisa cl\u00ednica, anunciou hoje uma transi\u00e7\u00e3o de lideran\u00e7a. Mary\u00a0Gunn","protected":false},"author":1,"featured_media":113909,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[27],"tags":[750,752,751],"class_list":["post-113908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-prnewswire","tag-a-emerald-clinical-trials","tag-anunciou-hoje-uma-transicao-de-lideranca-mary-gunn-deixou-o-cargo-imediatamente-a-diretor","tag-uma-das-principais-organizacoes-globais-em-pesquisa-clinica"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"SINGAPURA, 31 de julho de 2025 \/PRNewswire\/ &#8212; A Emerald Clinical Trials, uma das principais organiza\u00e7\u00f5es globais em pesquisa cl\u00ednica, anunciou hoje uma transi\u00e7\u00e3o de lideran\u00e7a. Mary\u00a0Gunn\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-31T15:27:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2025\/07\/1_53_2_2025-07-31_20.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO\",\"datePublished\":\"2025-07-31T15:27:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/\"},\"wordCount\":446,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1_53_2_2025-07-31_20.jpg\",\"keywords\":[\"A Emerald Clinical Trials\",\"anunciou hoje uma transi\u00e7\u00e3o de lideran\u00e7a. Mary\u00a0Gunn deixou o cargo imediatamente.\u00a0A diretor\",\"uma das principais organiza\u00e7\u00f5es globais em pesquisa cl\u00ednica\"],\"articleSection\":[\"PR Newswire\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/\",\"name\":\"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1_53_2_2025-07-31_20.jpg\",\"datePublished\":\"2025-07-31T15:27:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1_53_2_2025-07-31_20.jpg\",\"contentUrl\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1_53_2_2025-07-31_20.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/","og_locale":"pt_BR","og_type":"article","og_title":"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"SINGAPURA, 31 de julho de 2025 \/PRNewswire\/ &#8212; A Emerald Clinical Trials, uma das principais organiza\u00e7\u00f5es globais em pesquisa cl\u00ednica, anunciou hoje uma transi\u00e7\u00e3o de lideran\u00e7a. Mary\u00a0Gunn","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2025-07-31T15:27:00+00:00","og_image":[{"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2025\/07\/1_53_2_2025-07-31_20.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO","datePublished":"2025-07-31T15:27:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/"},"wordCount":446,"commentCount":0,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2025\/07\/1_53_2_2025-07-31_20.jpg","keywords":["A Emerald Clinical Trials","anunciou hoje uma transi\u00e7\u00e3o de lideran\u00e7a. Mary\u00a0Gunn deixou o cargo imediatamente.\u00a0A diretor","uma das principais organiza\u00e7\u00f5es globais em pesquisa cl\u00ednica"],"articleSection":["PR Newswire"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/","name":"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2025\/07\/1_53_2_2025-07-31_20.jpg","datePublished":"2025-07-31T15:27:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#primaryimage","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2025\/07\/1_53_2_2025-07-31_20.jpg","contentUrl":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-content\/uploads\/2025\/07\/1_53_2_2025-07-31_20.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/emerald-clinical-trials-confirma-plano-de-transicao-e-continuidade-de-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"Emerald Clinical Trials confirma plano de transi\u00e7\u00e3o e continuidade de CEO"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/113908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=113908"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/113908\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media\/113909"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=113908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=113908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=113908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}